SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
-14.12%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$469M
AUM Growth
+$469M
(-25%)
Cap. Flow
-$72.5M
Cap. Flow
% of AUM
-15.46%
Top 10 Holdings %
Top 10 Hldgs %
55.66%
Holding
40
New
3
Increased
12
Reduced
16
Closed
9
Top Buys
| 1 |
Incyte
INCY
|
$12.5M |
| 2 |
CVS Health
CVS
|
$7.17M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$5.92M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$5.47M |
| 5 |
Perrigo
PRGO
|
$4.02M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$16.2M |
| 2 |
Bristol-Myers Squibb
BMY
|
$16.1M |
| 3 |
Abbott
ABT
|
$15.4M |
| 4 |
Qiagen
QGEN
|
$14.7M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Bristol-Myers Squibb
BMY
$96B
| $37.8M | 8.05% | 677,433 -288,000 | -30% | -$16.1M |
|
|
2
Incyte
INCY
$16.5B
| $33.1M | 7.07% | 452,583 +170,041 | +60% | +$12.5M |
|
3
Boston Scientific
BSX
$156B
| $31.7M | 6.76% | 970,982 -66,041 | -6% | -$2.15M |
|
|
4
Abbott
ABT
$231B
| $29.2M | 6.23% | 370,334 -195,663 | -35% | -$15.4M |
|
5
Merck
MRK
$210B
| $28.7M | 6.11% | 372,695 +17,900 | +5% | +$1.38M |
|
6
Biogen
BIIB
$19.4B
| $23.8M | 5.07% | 75,120 -27,099 | -27% | -$8.57M |
|
7
Revvity
RVTY
$10.5B
| $21M | 4.47% | 278,522 -29,577 | -10% | -$2.23M |
|
8
Elevance Health
ELV
$71.8B
| $20.3M | 4.34% | 89,602 +13,094 | +17% | +$2.97M |
|
9
Agilent Technologies
A
$35.7B
| $18.4M | 3.92% | 256,716 -21,711 | -8% | -$1.55M |
|
|
10
Perrigo
PRGO
$3.27B
| $17.1M | 3.65% | 356,240 +83,596 | +31% | +$4.02M |
|
|
NUVA
11
DELISTED
NuVasive, Inc.
NUVA
| $15.9M | 3.4% | 314,828 -72,752 | -19% | -$3.69M |
|
12
United Therapeutics
UTHR
$13.8B
| $15.4M | 3.29% | 162,554 +11,939 | +8% | +$1.13M |
|
13
Johnson & Johnson
JNJ
$427B
| $15.4M | 3.29% | 117,532 +303 | +0.3% | +$39.7K |
|
|
ALXN
14
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $15.1M | 3.23% | 168,503 +42,339 | +34% | +$3.8M |
|
|
15
Gilead Sciences
GILD
$140B
| $14.9M | 3.18% | 199,419 -216,186 | -52% | -$16.2M |
|
16
Humana
HUM
$36.5B
| $14M | 2.99% | 44,657 -604 | -1% | -$190K |
|
17
Ionis Pharmaceuticals
IONS
$6.79B
| $13M | 2.78% | 275,481 +57,846 | +27% | +$2.74M |
|
|
18
BioMarin Pharmaceuticals
BMRN
$11.2B
| $11.8M | 2.51% | 139,582 +64,679 | +86% | +$5.47M |
|
19
Bruker
BRKR
$5.16B
| $11.7M | 2.5% | 326,846 -14,904 | -4% | -$534K |
|
20
Bio-Rad Laboratories Class A
BIO
$8.06B
| $11.4M | 2.43% | 32,470 -12,400 | -28% | -$4.35M |
|
21
Elanco Animal Health
ELAN
$9.12B
| $11.2M | 2.4% | 501,762 +68,285 | +16% | +$1.53M |
|
22
Cardinal Health
CAH
$35.5B
| $9.98M | 2.13% | 208,192 -4,371 | -2% | -$210K |
|
23
Quest Diagnostics
DGX
$20.3B
| $9.08M | 1.94% | 113,042 +36,066 | +47% | +$2.9M |
|
|
PDCO
24
DELISTED
Patterson Companies, Inc.
PDCO
| $8.11M | 1.73% | 530,217 +52,862 | +11% | +$808K |
|
|
25
CVS Health
CVS
$92.8B
| $7.17M | 1.53% | +120,860 | New | +$7.17M |
|